The Evolution of Drug Resistant Epilepsy Treatment Options over the Past Century
Sunday, December 5, 2021
-
You may need to log in to view video on this page.
OVERVIEW:
Drug resistant epilepsy (DRE) is a difficult-to-treat disease consisting of one-third of all epilepsy patients. In the first part of the symposium, we will present the evolution of DRE treatment options over the past century. We will focus on the evolution of both antiseizure medications and nonpharmacological treatment options, including surgery and neuromodulation and evidence to support their use. The second portion of the symposium will focus on the future of epilepsy treatment algorithms by discussing precision medicine for DRE patients. We will discuss factors for early identification of patients at higher risk for DRE, early research into biomarkers that maybe used to predict pharmacological treatment success, and how precision medicine can be used preoperatively to identify the ideal surgical candidate. The goal of this symposium is to juxtapose pharmacological and surgical options for treating DRE, while also presenting what biomarkers are available currently.
Sponsor: LivaNova
Learning Objectives:
Following participation in this activity, learners will be able to:
- Discuss the evolution of pharmacological and nonpharmacological treatment options for DRE over the past century.
- Recognize the utility of surgical treatment options for DRE patients.
- Appreciate the current advances in precision medicine for identifying and treating DRE patients.
- Discuss what biomarker evidence can be utilized today to help treat DRE patients.